IMMUNOVANT ($IMVT) posted quarterly earnings results for Q4 2026 on Wednesday, May 20th. The company reported earnings of -$0.73 per share, missing estimates of -$0.61 by $0.12. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $IMVT stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
IMMUNOVANT Insider Trading Activity
IMMUNOVANT insiders have traded $IMVT stock on the open market 25 times in the past 6 months. Of those trades, 1 have been purchases and 24 have been sales.
Here’s a breakdown of recent trading of $IMVT stock by insiders over the last 6 months:
- SCIENCES LTD. ROIVANT purchased 16,666,666 shares for an estimated $349,999,986
- TIAGO GIRAO (Chief Financial Officer) sold 25,760 shares for an estimated $763,011
- MELANIE GLORIA (Chief Operating Officer) has made 0 purchases and 6 sales selling 24,586 shares for an estimated $604,988.
- ANDREW J. FROMKIN has made 0 purchases and 2 sales selling 22,249 shares for an estimated $517,189.
- TUYL CHRISTOPHER VAN (Chief Legal Officer) has made 0 purchases and 4 sales selling 18,855 shares for an estimated $491,028.
- JAY S STOUT (Chief Technology Officer) has made 0 purchases and 6 sales selling 16,066 shares for an estimated $416,526.
- DOUGLAS J. HUGHES has made 0 purchases and 2 sales selling 15,000 shares for an estimated $348,665.
- ERIC VENKER (Chief Executive Officer) has made 0 purchases and 2 sales selling 14,229 shares for an estimated $342,854.
- ROBERT GRAHAM SUSMAN sold 2,502 shares for an estimated $67,979
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
IMMUNOVANT Hedge Fund Activity
We have seen 135 institutional investors add shares of IMMUNOVANT stock to their portfolio, and 80 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 4,591,235 shares (-88.9%) from their portfolio in Q4 2025, for an estimated $116,709,193
- TCG CROSSOVER MANAGEMENT, LLC added 2,797,055 shares (+168.4%) to their portfolio in Q1 2026, for an estimated $68,933,420
- JENNISON ASSOCIATES LLC added 2,496,241 shares (+356.4%) to their portfolio in Q1 2026, for an estimated $61,519,859
- ARMISTICE CAPITAL, LLC removed 2,182,239 shares (-38.0%) from their portfolio in Q1 2026, for an estimated $53,781,280
- POINT72 ASSET MANAGEMENT, L.P. removed 2,000,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $49,290,000
- FARALLON CAPITAL MANAGEMENT LLC added 1,534,000 shares (+12783.3%) to their portfolio in Q1 2026, for an estimated $37,805,430
- MORGAN STANLEY removed 969,508 shares (-20.0%) from their portfolio in Q1 2026, for an estimated $23,893,524
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
IMMUNOVANT Price Targets
Multiple analysts have issued price targets for $IMVT recently. We have seen 5 analysts offer price targets for $IMVT in the last 6 months, with a median target of $35.0.
Here are some recent targets:
- Corinne Johnson from Goldman Sachs set a target price of $32.0 on 04/15/2026
- Douglas Tsao from HC Wainwright & Co. set a target price of $35.0 on 02/10/2026
- Yatin Suneja from Guggenheim set a target price of $44.0 on 02/09/2026
- Danielle Brill from Truist Securities set a target price of $22.0 on 01/08/2026
- Andy Chen from Wolfe Research set a target price of $50.0 on 01/06/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
